Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Capital Expenditures data on file, last reported at $2.5 million in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 51.44% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 67.23% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, up 697.15% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.5 million, down from $10.8 million in the prior quarter.
• Over the last five years, Capital Expenditures for DNLI reached as high as $12.9 million in Q4 2023 and fell as low as -$10.7 million in Q3 2025.
• Historically, Capital Expenditures has averaged $1.5 million across 5 years, with a median of $2.5 million in 2026.
• Across the five-year window, Capital Expenditures tumbled 3225.0% in 2022 and surged 77092.86% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at -$284000.0 in 2022, then jumped by 4655.99% to $12.9 million in 2023, then sank by 99.89% to $14000.0 in 2024, then jumped by 77092.86% to $10.8 million in 2025, then tumbled by 77.18% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $2.5 million in Q1 2026, $10.8 million in Q4 2025, and -$10.7 million in Q3 2025.